Non-Profit Says $850000 Gene Therapy Is At Least Twice As Expensive As It Should Be – Forbes
Non-Profit Says $850000 Gene Therapy Is At Least Twice As Expensive As It Should Be
Earlier this month, Spark Therapeutics announced that its gene therapy Luxturna, for a rare form of blindness, would cost $850,000 a year. The price was below the $1 million-plus price tag many had expected, and was called fair by the chief medical ...
Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
Payers point to Spark's gene therapy as a model for innovative pricing plans
At $850000, price for new childhood blindness gene therapy four times too high, analysis says